Sarepta Therapeutics Stock Plummets to 2nd in Trading Volume Ranking Amid Patient Death Concerns

On June 17, 2025, Sarepta Therapeutics (SRPT) experienced a significant drop in trading volume, with a 67.35% decrease compared to the previous day, resulting in a trading volume of $291 million. Despite this, the stock price managed to rise by 2.77%.

Sarepta Therapeutics faced a substantial setback after announcing the death of a second patient following treatment with its Duchenne muscular dystrophy gene therapy, Elevidys. This news led to a sharp decline in the company's stock price, as investors reacted to the potential risks associated with the therapy.

The company's shares plummeted in response to the news, with multiple analysts downgrading the stock. The second fatality linked to Elevidys raised concerns about the safety and efficacy of the gene therapy, leading to a significant drop in investor confidence.

Sarepta Therapeutics' stock price has been under pressure since the first death was reported in March. The company's shares dropped 27% following that incident, and the latest fatality has further exacerbated investor concerns. Analysts have warned of potential risks to the company's 2025 revenue guidance and the overall viability of its gene therapy program.